These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36542988)

  • 1. Development and validation of a liquid chromatography coupled to tandem mass spectrometry method for the monitoring of temsavir plasma concentrations in people living with HIV.
    Thoueille P; Seybold U; Decosterd LA; Desfontaine V
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Jan; 1214():123575. PubMed ID: 36542988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method for quantifying lenacapavir plasma concentrations: Application to therapeutic monitoring.
    West RE; Oberly PJ; Riddler SA; Nolin TD; Devanathan AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Nov; 1230():123905. PubMed ID: 37866010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to quantify antiretroviral drug concentrations in human plasma for therapeutic monitoring.
    West RE; Oberly PJ; Riddler SA; Nolin TD; Devanathan AS
    J Pharm Biomed Anal; 2024 Mar; 240():115932. PubMed ID: 38198884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
    Courlet P; Alves Saldanha S; Cavassini M; Marzolini C; Choong E; Csajka C; Günthard HF; André P; Buclin T; Desfontaine V; Decosterd LA
    J Mass Spectrom; 2020 Jun; 55(6):e4506. PubMed ID: 32160389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action.
    West RE; Oberly PJ; Saylor AJ; Riddler SA; Nolin TD; Devanathan AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jul; 1241():124164. PubMed ID: 38823149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
    Courlet P; Spaggiari D; Desfontaine V; Cavassini M; Alves Saldanha S; Buclin T; Marzolini C; Csajka C; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1125():121733. PubMed ID: 31374423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.
    Wire MB; Magee M; Ackerman P; Llamoso C; Moore K
    HIV Res Clin Pract; 2021 Dec; 23(1):1-8. PubMed ID: 35285786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir.
    Magee M; Slater J; Mannino F; Ackerman P; Llamoso C; Moore K
    J Clin Pharmacol; 2021 Jul; 61(7):939-953. PubMed ID: 33368327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.
    Quaranta S; Woloch C; Paccou A; Giocanti M; Solas C; Lacarelle B
    Ther Drug Monit; 2009 Dec; 31(6):695-702. PubMed ID: 19865000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
    Simiele M; Ariaudo A; De Nicolò A; Favata F; Ferrante M; Carcieri C; Bonora S; Di Perri G; De Avolio A
    J Pharm Biomed Anal; 2017 May; 138():223-230. PubMed ID: 28219799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection.
    Chahine EB
    Am J Health Syst Pharm; 2021 Feb; 78(5):376-388. PubMed ID: 33547469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
    Aouri M; Calmy A; Hirschel B; Telenti A; Buclin T; Cavassini M; Rauch A; Decosterd LA
    J Mass Spectrom; 2013 May; 48(5):616-25. PubMed ID: 23674286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
    Gartland M; Cahn P; DeJesus E; Diaz RS; Grossberg R; Kozal M; Kumar P; Molina JM; Mendo Urbina F; Wang M; Du F; Chabria S; Clark A; Garside L; Krystal M; Mannino F; Pierce A; Ackerman P; Lataillade M
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0175121. PubMed ID: 35502922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
    Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
    Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UPLC-MS/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma.
    Gouget H; Noé G; Barrail-Tran A; Furlan V
    J Pharm Biomed Anal; 2020 Mar; 181():113057. PubMed ID: 31962247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
    Decosterd LA; Mercier T; Ternon B; Cruchon S; Guignard N; Lahrichi S; Pesse B; Rochat B; Burger R; Lamoth F; Pagani JL; Eggimann P; Csajka C; Choong E; Buclin T; Widmer N; André P; Marchetti O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1157():122160. PubMed ID: 32891946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
    Djerada Z; Feliu C; Tournois C; Vautier D; Binet L; Robinet A; Marty H; Gozalo C; Lamiable D; Millart H
    J Pharm Biomed Anal; 2013 Dec; 86():100-11. PubMed ID: 23995753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma.
    Tachet J; Versace F; Mercier T; Buclin T; Decosterd LA; Choong E; Girardin FR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Nov; 1230():123917. PubMed ID: 37956468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.